AGF Management’s Teva Pharmaceuticals TEVA Stock Holding History

AGF Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,744	Closed	-$384K	–	731
2026 Q1	$384K	Sell	12,744 -5,925	-32%	-$191K	﹤0.01%	608
2025 Q4	$583K	Hold	18,669	–	–	﹤0.01%	592
2025 Q3	$377K	Buy	+18,669	New	+$328K	﹤0.01%	617
2025 Q2	–	Sell	-10,316	Closed	-$159K	–	727
2025 Q1	$159K	Hold	10,316	–	–	﹤0.01%	654
2024 Q4	$227K	Hold	10,316	–	–	﹤0.01%	673
2024 Q3	$186K	Buy	+10,316	New	+$181K	﹤0.01%	663
2024 Q1	–	Sell	-21,869	Closed	-$228K	–	767
2023 Q4	$228K	Buy	+21,869	New	+$204K	﹤0.01%	700
2023 Q2	–	Sell	-26,937	Closed	-$238K	–	757
2023 Q1	$238K	Buy	26,937 +12,014	+81%	+$119K	﹤0.01%	723
2022 Q4	$136K	Buy	+14,923	New	+$130K	﹤0.01%	740

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

AGF Management's TEVA Position: Q2 2026 in Review

AGF Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 12,744 shares — an estimated $384K sold.

AGF Management first reported a position in TEVA in Q4 2022 and held it in 9 quarters. The position peaked at $583K in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

AGF Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
AGF Management sold 12,744 Teva Pharmaceuticals shares in Q2 2026, an estimated $384K.
AGF Management first reported a position in Teva Pharmaceuticals in Q4 2022 and held it in 9 quarters.
AGF Management's Teva Pharmaceuticals position peaked at $583K in Q4 2025.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on AGF Management's 13F filing for Q2 2026, filed 10 Aug 2026.